ACTRN12621000928819Recruiting未知
Cessation Of Pharmacotherapy In Recovered Chemotherapy induced cardioToxicity (COP-RCT) – a pilot study
epean Blue Mountains Local Health District0 sites70 target enrollmentStarted: July 15, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 17 Years to 80 Years (—)
- Sex
- All
Inclusion Criteria
- •Previously diagnosed asymptomatic chemotherapy related cardiac dysfunction (CTRCD) (defined as: LVEF drop >10% to a value below <55% from baseline or GLS drop greater than or equal to 12% from baseline)
- •LVEF of >50%.
- •NYHA Class I
- •Current CTRCD therapy – Angiotensin Converting Enzyme inhibitor (ACEi) AND/OR Beta Blocker (BB)
- •Completed HER2 receptor therapy (traztuzumab/pertuzumab)
Exclusion Criteria
- •History of ischaemic heart disease
- •Hypertension requiring medical therapy
- •Moderate or greater severity valvular disease
- •Chronic kidney disease
- •Atrial, supraventricular, or ventricular arrhythmia requiring BB therapy
- •Pregnancy
- •< 16 years old
Investigators
Similar Trials
Not yet recruiting
Phase 4
COP-RCTCancerJPRN-jRCT1030230265Miyazaki Sakiko4
Recruiting
Phase 1
Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)MedDRA version: 20.0Level: LLTClassification code: 10019279Term: Heart failure Class: 10007541Heart FailureCTIS2023-504946-70-00Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia60
Active, not recruiting
Phase 1
Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized studyHeart failureEUCTR2021-001327-41-ESFundación para la formación e investigación sanitarias de la Región de Murcia60
Completed
Not Applicable
The effect of premature chemotherapy termination in breast cancer on relapseC50.9Breast, unspecifiedDRKS00022566Ortenau-Klinikum Offenburg-Kehl1,916
Completed
Not Applicable
Systematic Termination of Pharmaceutical Agents Trial (STOPAT): a pilot randomised trial of stopping drug therapyPolypharmacyPublic Health - Other public healthACTRN12610000865011Royal Perth Hospital40